22 results about "Endocrine therapy" patented technology

The present disclosure relates to a panel of ER regulated genes and method for using the panel for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant using the panel, then determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant using the panel, and comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant.

The present application relates to a kind of SGLT2 inhibitor in the preparation for treating hormone receptor low reaction type reproductive system disease in the application of drug, in particular, SGLT2 inhibitor and hormone can improve or enhance the sensitivity and / or for reversing the drug resistance of endocrine therapy drug, such as hormone, can enhance the therapeutic effect of such drug, especially in drug-resistant reproductive system disease and tumor treatment has good application prospect.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

Methods of treatment, methods of detection, and kits associated with ERα+ cancer, such as ERα+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifying cancer estrogen receptor status, and identifying appropriate therapeutic regimens in an individualized manner.

The invention discloses a primer and probe combination for detecting ESR1 gene drug-resistant mutation sites based on a digital PCR single tube and application of the primer and probe combination, and belongs to the technical field of molecular detection, sequences of primers are shown as SEQ ID NO.1-2, sequences of probes are shown as SEQ ID NO.3-4, and 5'ends of the two probes are marked with different fluorophores. According to the present invention, with the primer probe combination, the high-sensitivity and rapid detection of the common nine drug-resistant related mutation sites such as L536H, L536Q, L536R, L536P, Y537S, Y537C, Y537N, Y537D and D538G of the ESR1 gene in the breast cancer through the single tube can be achieved, such that the ESR1 gene detection efficiency is substantially improved, and the detection cost is reduced so as to guide the endocrine treatment of the breast cancer.

This disclosure relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) disclosed herein, and a monoclonal antibody or an antibody-drug conjugate, optionally in further combination with an endocrine therapy agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.

The present disclosure relates to adjuvant treatment of HR + / HER2-phase II or III early breast cancer in adult patients. The methods comprise administering a rebosilil (CDK4 / 6 inhibitor) in combination with endocrine therapy.

The present invention refers to the in vitro use of DNA copy number alterations (CNAs) for predicting the response of patients with HR+ / HER2− breast cancer to a treatment comprising targeted therapy, such as CDK4 / 6 inhibitors, and / or endocrine therapy; for the prognosis of patients with HR+ / HER2− breast cancer, for monitoring patients with HR+ / HER2− breast cancer, or for classifying patients with HR+ / HER2− breast cancer into responder or non-responder to a treatment comprising targeted therapy, such as CDK4 / 6 inhibitors, and / or endocrine therapy.

The application discloses a kind of multiple targeting photothermal-photo dynamic-endocrine three-mode synergistic treatment breast cancer nano-drug and its application, it is related to biological and new pharmaceutical technical field.The application is effectively inhibited the growth and metastasis of breast cancer cell by the three-mode synergistic effect of photothermal, photo dynamic and endocrine therapy, amphiphilic polymer based on Tcpp (four carboxyl phenyl porphyrin) It can be self-assembled to form nanoscale hollow regular sphere, using the high permeability and retention effect (EPR effect) of tumor site, realize the efficient accumulation of drug in tumor tissue;Prodrug BHP is realized by combining photothermal group and palbociclib, and the synergistic effect of multiple action mechanisms, so as to improve the treatment effect.The nano-drug prepared by the application has good safety and biocompatibility, and exhibits significant antitumor effect in tumor-bearing nude mouse model, which provides a new strategy and idea for the treatment of breast cancer.

The present disclosure provides a method of treating breast cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a radiopharmaceutical compound having a GRPR antagonist moiety, e.g., 177 [0013] The present invention relates to a method comprising administering to the subject [0014] Lu]Lu-NeoB in combination with a CDK4 / 6 inhibitor, e.g., ribocicilib, and a therapeutically effective amount of an endocrine therapy, e.g., fulvestrant.

This disclosure relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) disclosed herein, and a monoclonal antibody or an antibody-drug conjugate, optionally in further combination with an endocrine therapy agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.

The invention relates to the technical field of software, and discloses a prostate cancer endocrine therapy patient physiological feature dynamic early warning system, which comprises a core processing module, which is configured to dynamically distribute analysis weights for different types of monitoring data based on the current endocrine therapy duration of a patient, the analysis weight of the high-frequency physiological symptom data is improved in the treatment induction period, and the analysis weight of the function and behavior data is improved in the long-term maintenance period; setting an individualized baseline of the monitoring data; according to the periodic clinical calibration data, carrying out adaptive adjustment on the analysis weight and the individualized baseline; for a preset function or behavior index, calculating an accumulated integral of the deviation of the monitoring data relative to the individualized baseline in the sliding time window, and calculating to obtain a risk score; the system provided by the invention can distinguish trends needing long-term attention, changes worthy of reminding attention and dangers which must be processed immediately, and gives responses of different levels.

The present invention relates to a method of determining the therapy for treating a subject afflicted from breast cancer comprising determining the P27 T2871099G SNP in a sample of said subject and administering only endocrine therapy if the polymorphism is other than T2871099G, and administering endocrine therapy in combination with at least one CDK4 / 6 inhibitor if the polymorphism is homozygous T2871099G.

The application provides use of CYP2A6 genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy for breast cancer, patients with CYP2A6 intermediate / slow metabolism type are more likely to achieve pCR than patients with normal metabolism type, CYP2A6 rs61663607 T>C TT type is more likely to achieve pCR than TC and CC types, in patients with neoadjuvant chemotherapy combined with or without letrozole, CYP2A6 rs7250713 G>C CC type is more likely to achieve pCR than CC and CG types. The application also provides use of CYP2A6 genotype in preparation of a reagent for diagnosing and predicting the efficacy of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy for breast cancer. The application is used for auxiliary diagnosis of the efficacy of neoadjuvant chemotherapy combined with or without letrozole treatment for early hormone receptor positive breast cancer patients receiving neoadjuvant therapy and surgery.

The application discloses a prostate cancer endocrine therapy drug resistance prediction system based on a multi-model artificial intelligence, which comprises a data acquisition and preprocessing module, a single-omics prediction module, a multi-modal feature integration module, a model training module and a prediction result output module. The multi-omics data of the patient is acquired and preprocessed, the data representation of the omics data with different labels is generated by using prior knowledge, the best single-omics prediction model is matched for the omics data with different labels based on the data representation enhanced by the knowledge, the best single-omics prediction model corresponding to the medical data with different labels is constructed into a multi-omics prediction model of the prostate cancer endocrine therapy drug resistance by using Stacking, the drug resistance risk of the patient within a preset time is predicted and an early warning is output, and the treatment scheme of the patient is adjusted according to the drug resistance risk. The application integrates the multi-omics data, constructs a precise multi-omics prediction model of the prostate cancer endocrine therapy drug resistance, and improves the accuracy and clinical applicability of the drug resistance prediction.

The invention relates to the technical field of biomedicine, and discloses a method for predicting breast cancer in-situ recurrence by using specific microorganisms of cancer tissues. According to the method for predicting breast cancer in-situ recurrence by using the specific microorganisms of the cancer tissue, a recurrence scoring system is constructed for prediction by amplifying the specific sequences of the microorganisms of the cancer tissue. According to the principle of tissue microorganism difference of relapse and non-relapse patients, the detection kit is composed of reagents with specific sequences amplified by Real-Time qPCR and three pairs of primers, and the breast cancer relapse risk is predicted by detecting the proportion of aerobic microorganisms to obligate anaerobic microorganisms. The method for predicting breast cancer in-situ recurrence has the characteristics of high accuracy and low false positive rate, and is used for clinically evaluating whether endocrine therapeutic drugs are used or not to provide reference.

The present disclosure relates to a panel of ER-regulated genes and a method for using the panel to monitor the response of an individual with cancer to treatment with amsenestrant, the method comprising: determining a first ER activity score from a sample from the individual at a first time point prior to treatment with amsenestrant using the panel; then determining a second ER activity score from a sample from the individual at a second time point after administration of amsenestrant using the panel; and comparing the first ER activity score to the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amsenestrant.

Provided herein is method of treating vasomotor symptoms (VMS) in a breast cancer patient being treated with an endocrine therapy drug comprising administering fezolinetant.

This disclosure relates to adjuvant therapy for HR+ / HER2- stage II or III early breast cancer in adult patients. The method involves administering ribociclib (a CDK4 / 6 inhibitor) in combination with endocrine therapy.

The application relates to the technical field of software, and discloses a dynamic early warning system for physiological characteristics of prostate cancer endocrine therapy patients, which comprises a core processing module configured to: dynamically allocate analysis weights for different categories of monitoring data based on the current endocrine therapy duration of a patient, wherein the analysis weight of high-frequency physiological symptom category data is increased in a treatment induction period, and the analysis weight of function and behavior category data is increased in a long-term maintenance period; setting an individualized baseline of monitoring data; adaptively adjusting the analysis weight and the individualized baseline according to periodic clinical calibration data; calculating the cumulative integral of the deviation of monitoring data relative to the individualized baseline in a sliding time window for a preset function or behavior index, and calculating a risk score; the system can distinguish between trends that need long-term attention, changes that are worth reminding, and dangers that must be immediately handled, and different levels of responses are given.